R&D Pipeline

Vaccines, Patents, R&D, Clinical Research, Phase I, Phase II, Phase III, Licensure & Partnerships.
DISCOVER MORE!

Innovative technologies

Our team of scientists is committed to creating innovative technologies for the production of vaccines against infectious diseases such as whooping cough, dengue or meningitis.

Our approach

Our R&D approach is centered on exploiting the most recent cutting-edge technology platforms available in the field of genetic engineering, protein conjugation, cell-culture and formulation so as to develop new and affordable vaccines using highly efficient production process.

Recombinant aP Family

Nucleic Acid Vaccines

Recombinant Viral Vaccines

Recombinant aP Family

Recombinant aP

Recombinant pertussis vaccine (aPgen)
R&D
100%
Pre-clinical
100%
Clinical
100%
.
100%
.
100%
Licensure
100%

Recombinant TdaP

Tetanus toxoid, reduced diphtheria toxoid and recombinant pertussis vaccine (TdaPgen)
R&D
100%
Pre-clinical
100%
Clinical
100%
.
100%
.
100%
Licensure
100%

Recombinant Tdap

Tetanus toxoid, reduced diphtheria toxoid, reduced recombinant pertussis vaccine (Tdapgen)
R&D
100%
Pre-clinical
100%
Clinical
100%
.
100%
.
100%
Licensure
100%

Recombinant ap

Reduced recombinant pertussis vaccine (apgen)
R&D
100%
Pre-clinical
100%
Clinical
100%
.
100%
.
100%
Licensure
50%

Pediatric DTaP

Diphtheria toxoid, tetanus toxoid, recombinant pertussis vaccine
R&D
100%
Pre-clinical
100%
Clinical
100%
.
100%
.
50%
Licensure
50%
pipeline

Nucleic Acid Vaccines

DNA COVID-19

R&D
100%
Pre-clinical
100%
Clinical
100%
.
50%
.
50%
Licensure
100%

DNA COVID-19 Variants

COVID-19
R&D
100%
Pre-clinical
100%
Clinical
50%
.
50%
.
50%
Licensure
100%

mRNA COVID-19

COVID-19
R&D
100%
Pre-clinical
100%
Clinical
100%
.
100%
.
50%
Licensure
100%

DNA Zika/Dengue

Zika/Dengue
R&D
100%
Pre-clinical
100%
Clinical
50%
.
50%
.
50%
Licensure
100%
pipeline

Recombinant Viral Vaccines

Chikungunya

Chikungunya
R&D
100%
Pre-clinical
50%
Clinical
50%
.
50%
.
50%
Licensure
50%

HBV

Hepatitis B
R&D
100%
Pre-clinical
50%
Clinical
50%
.
50%
.
50%
Licensure
50%

HPV

Human papillomavirus
R&D
100%
Pre-clinical
50%
Clinical
50%
.
50%
.
50%
Licensure
50%
pipeline